Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
25
PTHS Quote, Financials, Valuation and Earnings
Last price:
$26.53
Seasonality move
:
225.3%
Day range:
$25.27 - $27.20
52-week range:
$6.01 - $54.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.28x
P/B ratio:
0.31x
Volume:
8.5K
Avg. volume:
25K
1-year change:
331.75%
Market cap:
$17.9M
Revenue:
--
EPS (TTM):
-$14.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PTHS
Pelthos Therapeutics, Inc.
|
$4.4M | -$0.58 | -- | -5.39% | $59.80 |
|
AGEN
Agenus, Inc.
|
$80.4M | $2.20 | 97.85% | -36.28% | $12.33 |
|
INBX
Inhibrx Biosciences, Inc.
|
-- | -$1.72 | -100% | -37.09% | $12.00 |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$58.8M | $1.93 | 29.84% | -74.47% | $243.44 |
|
PVLA
Palvella Therapeutics, Inc.
|
-- | -$0.85 | -- | -21.1% | $182.57 |
|
TVTX
Travere Therapeutics, Inc.
|
$106.1M | -$0.09 | 90.12% | -87.94% | $41.6429 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PTHS
Pelthos Therapeutics, Inc.
|
$27.20 | $59.80 | $17.9M | -- | $0.00 | 0% | 9.28x |
|
AGEN
Agenus, Inc.
|
$3.19 | $12.33 | $108.5M | -- | $0.00 | 0% | 0.81x |
|
INBX
Inhibrx Biosciences, Inc.
|
$79.27 | $12.00 | $1.1B | 0.20x | $0.00 | 0% | 861.92x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$195.16 | $243.44 | $3.8B | 93.93x | $0.00 | 0% | 15.29x |
|
PVLA
Palvella Therapeutics, Inc.
|
$101.15 | $182.57 | $1.2B | -- | $0.00 | 0% | -- |
|
TVTX
Travere Therapeutics, Inc.
|
$39.6400 | $41.6429 | $3.5B | -- | $0.00 | 0% | 8.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PTHS
Pelthos Therapeutics, Inc.
|
5.64% | 7.137 | 18.84% | 0.90x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.383 | 285.06% | 0.03x |
|
INBX
Inhibrx Biosciences, Inc.
|
74.38% | 2.603 | 21.93% | 4.26x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
32.19% | 1.626 | 12.95% | 23.64x |
|
PVLA
Palvella Therapeutics, Inc.
|
29.29% | 0.000 | 2.3% | 6.16x |
|
TVTX
Travere Therapeutics, Inc.
|
81.76% | 1.077 | 15.42% | 2.50x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PTHS
Pelthos Therapeutics, Inc.
|
$4M | -$15.4M | -192.61% | -241.95% | -207.43% | -$15.3M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
INBX
Inhibrx Biosciences, Inc.
|
-$582K | -$33.8M | -92.1% | -151.49% | -2106.85% | -$33.8M |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$103.6M | $54.1M | 5.15% | 5.72% | 46.85% | $4.8M |
|
PVLA
Palvella Therapeutics, Inc.
|
-- | -$10.2M | -86.19% | -101.06% | -- | -$7.9M |
|
TVTX
Travere Therapeutics, Inc.
|
$147.5M | $24.9M | -21.07% | -263.9% | 15.12% | -$871K |
Pelthos Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PTHS or AGEN?
Agenus, Inc. has a net margin of -219.26% compared to Pelthos Therapeutics, Inc.'s net margin of -116.82%. Pelthos Therapeutics, Inc.'s return on equity of -241.95% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PTHSPelthos Therapeutics, Inc.54.31% -$5.30 $61.7M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About PTHS or AGEN?
Pelthos Therapeutics, Inc. has a consensus price target of $59.80, signalling upside risk potential of 119.85%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 286.63%. Given that Agenus, Inc. has higher upside potential than Pelthos Therapeutics, Inc., analysts believe Agenus, Inc. is more attractive than Pelthos Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTHSPelthos Therapeutics, Inc.5 0 0 AGENAgenus, Inc.2 1 0 -
Is PTHS or AGEN More Risky?
Pelthos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.01%.
-
Which is a Better Dividend Stock PTHS or AGEN?
Pelthos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pelthos Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTHS or AGEN?
Pelthos Therapeutics, Inc. quarterly revenues are $7.4M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Pelthos Therapeutics, Inc.'s net income of -$16.2M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Pelthos Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pelthos Therapeutics, Inc. is 9.28x versus 0.81x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTHSPelthos Therapeutics, Inc.9.28x -- $7.4M -$16.2M AGENAgenus, Inc.0.81x -- $30.2M $63.9M
-
Which has Higher Returns PTHS or INBX?
Inhibrx Biosciences, Inc. has a net margin of -219.26% compared to Pelthos Therapeutics, Inc.'s net margin of -2204.15%. Pelthos Therapeutics, Inc.'s return on equity of -241.95% beat Inhibrx Biosciences, Inc.'s return on equity of -151.49%.
Company Gross Margin Earnings Per Share Invested Capital PTHSPelthos Therapeutics, Inc.54.31% -$5.30 $61.7M INBXInhibrx Biosciences, Inc.49.08% -$2.28 $143.7M -
What do Analysts Say About PTHS or INBX?
Pelthos Therapeutics, Inc. has a consensus price target of $59.80, signalling upside risk potential of 119.85%. On the other hand Inhibrx Biosciences, Inc. has an analysts' consensus of $12.00 which suggests that it could fall by -84.86%. Given that Pelthos Therapeutics, Inc. has higher upside potential than Inhibrx Biosciences, Inc., analysts believe Pelthos Therapeutics, Inc. is more attractive than Inhibrx Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTHSPelthos Therapeutics, Inc.5 0 0 INBXInhibrx Biosciences, Inc.0 1 0 -
Is PTHS or INBX More Risky?
Pelthos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inhibrx Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PTHS or INBX?
Pelthos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inhibrx Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pelthos Therapeutics, Inc. pays -- of its earnings as a dividend. Inhibrx Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTHS or INBX?
Pelthos Therapeutics, Inc. quarterly revenues are $7.4M, which are larger than Inhibrx Biosciences, Inc. quarterly revenues of --. Pelthos Therapeutics, Inc.'s net income of -$16.2M is higher than Inhibrx Biosciences, Inc.'s net income of -$35.3M. Notably, Pelthos Therapeutics, Inc.'s price-to-earnings ratio is -- while Inhibrx Biosciences, Inc.'s PE ratio is 0.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pelthos Therapeutics, Inc. is 9.28x versus 861.92x for Inhibrx Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTHSPelthos Therapeutics, Inc.9.28x -- $7.4M -$16.2M INBXInhibrx Biosciences, Inc.861.92x 0.20x -- -$35.3M
-
Which has Higher Returns PTHS or LGND?
Ligand Pharmaceuticals, Inc. has a net margin of -219.26% compared to Pelthos Therapeutics, Inc.'s net margin of 10.18%. Pelthos Therapeutics, Inc.'s return on equity of -241.95% beat Ligand Pharmaceuticals, Inc.'s return on equity of 5.72%.
Company Gross Margin Earnings Per Share Invested Capital PTHSPelthos Therapeutics, Inc.54.31% -$5.30 $61.7M LGNDLigand Pharmaceuticals, Inc.89.7% $5.68 $1.4B -
What do Analysts Say About PTHS or LGND?
Pelthos Therapeutics, Inc. has a consensus price target of $59.80, signalling upside risk potential of 119.85%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $243.44 which suggests that it could grow by 24.74%. Given that Pelthos Therapeutics, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Pelthos Therapeutics, Inc. is more attractive than Ligand Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTHSPelthos Therapeutics, Inc.5 0 0 LGNDLigand Pharmaceuticals, Inc.6 0 0 -
Is PTHS or LGND More Risky?
Pelthos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.587%.
-
Which is a Better Dividend Stock PTHS or LGND?
Pelthos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pelthos Therapeutics, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTHS or LGND?
Pelthos Therapeutics, Inc. quarterly revenues are $7.4M, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $115.5M. Pelthos Therapeutics, Inc.'s net income of -$16.2M is lower than Ligand Pharmaceuticals, Inc.'s net income of $117.3M. Notably, Pelthos Therapeutics, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 93.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pelthos Therapeutics, Inc. is 9.28x versus 15.29x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTHSPelthos Therapeutics, Inc.9.28x -- $7.4M -$16.2M LGNDLigand Pharmaceuticals, Inc.15.29x 93.93x $115.5M $117.3M
-
Which has Higher Returns PTHS or PVLA?
Palvella Therapeutics, Inc. has a net margin of -219.26% compared to Pelthos Therapeutics, Inc.'s net margin of --. Pelthos Therapeutics, Inc.'s return on equity of -241.95% beat Palvella Therapeutics, Inc.'s return on equity of -101.06%.
Company Gross Margin Earnings Per Share Invested Capital PTHSPelthos Therapeutics, Inc.54.31% -$5.30 $61.7M PVLAPalvella Therapeutics, Inc.-- -$1.03 $54.7M -
What do Analysts Say About PTHS or PVLA?
Pelthos Therapeutics, Inc. has a consensus price target of $59.80, signalling upside risk potential of 119.85%. On the other hand Palvella Therapeutics, Inc. has an analysts' consensus of $182.57 which suggests that it could grow by 80.51%. Given that Pelthos Therapeutics, Inc. has higher upside potential than Palvella Therapeutics, Inc., analysts believe Pelthos Therapeutics, Inc. is more attractive than Palvella Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTHSPelthos Therapeutics, Inc.5 0 0 PVLAPalvella Therapeutics, Inc.14 0 0 -
Is PTHS or PVLA More Risky?
Pelthos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palvella Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PTHS or PVLA?
Pelthos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palvella Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pelthos Therapeutics, Inc. pays -- of its earnings as a dividend. Palvella Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTHS or PVLA?
Pelthos Therapeutics, Inc. quarterly revenues are $7.4M, which are larger than Palvella Therapeutics, Inc. quarterly revenues of --. Pelthos Therapeutics, Inc.'s net income of -$16.2M is lower than Palvella Therapeutics, Inc.'s net income of -$11.3M. Notably, Pelthos Therapeutics, Inc.'s price-to-earnings ratio is -- while Palvella Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pelthos Therapeutics, Inc. is 9.28x versus -- for Palvella Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTHSPelthos Therapeutics, Inc.9.28x -- $7.4M -$16.2M PVLAPalvella Therapeutics, Inc.-- -- -- -$11.3M
-
Which has Higher Returns PTHS or TVTX?
Travere Therapeutics, Inc. has a net margin of -219.26% compared to Pelthos Therapeutics, Inc.'s net margin of 15.59%. Pelthos Therapeutics, Inc.'s return on equity of -241.95% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.
Company Gross Margin Earnings Per Share Invested Capital PTHSPelthos Therapeutics, Inc.54.31% -$5.30 $61.7M TVTXTravere Therapeutics, Inc.89.46% $0.25 $403.3M -
What do Analysts Say About PTHS or TVTX?
Pelthos Therapeutics, Inc. has a consensus price target of $59.80, signalling upside risk potential of 119.85%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.6429 which suggests that it could grow by 5.05%. Given that Pelthos Therapeutics, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe Pelthos Therapeutics, Inc. is more attractive than Travere Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTHSPelthos Therapeutics, Inc.5 0 0 TVTXTravere Therapeutics, Inc.12 2 0 -
Is PTHS or TVTX More Risky?
Pelthos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.
-
Which is a Better Dividend Stock PTHS or TVTX?
Pelthos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pelthos Therapeutics, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTHS or TVTX?
Pelthos Therapeutics, Inc. quarterly revenues are $7.4M, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Pelthos Therapeutics, Inc.'s net income of -$16.2M is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Pelthos Therapeutics, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pelthos Therapeutics, Inc. is 9.28x versus 8.25x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTHSPelthos Therapeutics, Inc.9.28x -- $7.4M -$16.2M TVTXTravere Therapeutics, Inc.8.25x -- $164.9M $25.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 18.81% over the past day.
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Buy
63
GLTO alert for Dec 30
Galecto, Inc. [GLTO] is down 12.13% over the past day.
